Clinical Trial Detail

NCT ID NCT03589547
Title Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hina Khan
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Age Groups: senior adult

No variant requirements are available.